Ralf‐Dieter Hofheinz

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Thorsten Oliver Goetze · 1 shared paper, 2026 · strength 0.23
   • Paper Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from … DOI 10.1002/ijc.70280↗
2. Salah‐Eddin Al‐Batran · 1 shared paper, 2026 · strength 0.23
   • Paper Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from … DOI 10.1002/ijc.70280↗
3. Uwe Pelzer · 2 shared papers, 2020–2024 · strength 0.22
   • Paper Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Panc… DOI 10.1159/000538171↗
   • Paper CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in pati… DOI 10.1016/j.ejca.2020.06.032↗
4. Anna Lena Hohneck · 1 shared paper, 2023 · strength 0.18
   • Paper Patients with Advanced Pancreatic Cancer Treated with Mistletoe and Hyperthermia in Addition to Palliative Chemotherapy… DOI 10.3390/cancers15204929↗
5. Anke Reinacher‐Schick · 2 shared papers, 2012–2024 · strength 0.16
   • Paper Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Panc… DOI 10.1159/000538171↗
   • Paper Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic c… DOI 10.1038/bjc.2012.18↗
6. Andrea Tannapfel · 1 shared paper, 2024 · strength 0.13
   • Paper Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Panc… DOI 10.1159/000538171↗
7. Céline Lugnier · 1 shared paper, 2024 · strength 0.13
   • Paper Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Panc… DOI 10.1159/000538171↗
8. Jan Schildmann · 1 shared paper, 2024 · strength 0.13
   • Paper Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Panc… DOI 10.1159/000538171↗
9. Jochen M. Schmitt · 1 shared paper, 2024 · strength 0.13
   • Paper Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Panc… DOI 10.1159/000538171↗
10. Emmanouil Fokas · 1 shared paper, 2024 · strength 0.13
    • Paper Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Panc… DOI 10.1159/000538171↗
11. Bernhard Josef Wormann · 1 shared paper, 2024 · strength 0.13
    • Paper Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Panc… DOI 10.1159/000538171↗
12. Marcus Bahra · 1 shared paper, 2020 · strength 0.09
    • Paper CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in pati… DOI 10.1016/j.ejca.2020.06.032↗
13. Michael B. Ghadimi · 1 shared paper, 2020 · strength 0.09
    • Paper CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in pati… DOI 10.1016/j.ejca.2020.06.032↗
14. Jana Käthe Striefler · 1 shared paper, 2020 · strength 0.09
    • Paper CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in pati… DOI 10.1016/j.ejca.2020.06.032↗
15. Marianne Sinn · 1 shared paper, 2020 · strength 0.09
    • Paper CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in pati… DOI 10.1016/j.ejca.2020.06.032↗
16. Helmut Oettle · 1 shared paper, 2020 · strength 0.09
    • Paper CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in pati… DOI 10.1016/j.ejca.2020.06.032↗
17. Hanno B. Riess · 1 shared paper, 2020 · strength 0.09
    • Paper CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in pati… DOI 10.1016/j.ejca.2020.06.032↗
18. Wolfgang Ekkehard Schmidt · 2 shared papers, 2013–2017 · strength 0.08
    • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
    • Paper Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therap… DOI 10.1093/annonc/mdt270↗
19. Esther Endlicher · 2 shared papers, 2012–2013 · strength 0.05
    • Paper Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therap… DOI 10.1093/annonc/mdt270↗
    • Paper Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic c… DOI 10.1038/bjc.2012.18↗
20. Beate S. Schultheis · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
21. Markus Dommach · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
22. Sara De Dosso · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
23. Jens Thomas Siveke · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
24. Dirk Strumberg · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
25. Şuayib Yalçın · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.